FALSE POSITIVE RADIOIODINE POST-ABLATION SCAN IN SCALP REGION IN A WOMAN WHO USED HAIR COLORING REVEALED BY SPECT/CT.
Journal
AACE clinical case reports
ISSN: 2376-0605
Titre abrégé: AACE Clin Case Rep
Pays: United States
ID NLM: 101670593
Informations de publication
Date de publication:
Historique:
received:
14
01
2019
accepted:
04
06
2019
entrez:
23
1
2020
pubmed:
23
1
2020
medline:
23
1
2020
Statut:
epublish
Résumé
Radioiodine ablation with iodine-131 is a standard therapeutic procedure for patients diagnosed with differentiated thyroid carcinoma (DTC). We present a contamination artifact on whole-body scan (WBS), after radioiodine ablation due to papillary thyroid carcinoma. The hybrid imaging resolved the question of metastasis versus contamination. In the case of 35-year-old female patient we used a General Electric hybrid gamma camera with a high-energy-general-purpose collimator for performing WBS, and single photon emission computed tomography combined with low dose computed tomography (SPECT/CT) for the detection of any residual thyroid tissue or meta-static disease and at the same time ablation and treatment of any confirmed metastasis. A thyroid scan showed activity in the remnant thyroid tissue of the right lobe, but also laterally in the calvaria (left temporal region). The patient's neck ultra-sound and thyroglobulin level were not in favor of metastasis. A false positive finding due to hair coloring was concluded with SPECT/CT hybrid imaging. SPECT/CT scan can contribute to establishing a final diagnosis in patients being evaluated for atypical locations of radioactive iodine accumulation after ablative doses of radioactive iodine, distinguishing between metastases from DTC and false positive accumulations or artifacts.
Identifiants
pubmed: 31967060
doi: 10.4158/ACCR-2018-0593
pmc: PMC6876955
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e311-e315Informations de copyright
Copyright © 2019 AACE.
Déclaration de conflit d'intérêts
DISCLOSURE The authors have no multiplicity of interest to disclose.
Références
Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1459-68
pubmed: 21505897
Am J Nucl Med Mol Imaging. 2012;2(3):362-85
pubmed: 23133823
Radiol Technol. 2007 May-Jun;78(5):433-4
pubmed: 17519382
Ann Nucl Med. 2004 May;18(3):271-4
pubmed: 15233290
Eur J Endocrinol. 2006 Oct;155(4):495-512
pubmed: 16990649
World J Nucl Med. 2016 May-Aug;15(2):137-41
pubmed: 27134566
J Nucl Med Technol. 2013 Mar;41(1):43-5
pubmed: 23381679
Health Phys. 1980 Apr;38(4):467-81
pubmed: 7410072
J Nucl Med Technol. 2004 Sep;32(3):164-5
pubmed: 15347695